Australia's most trusted
source of pharma news
Monday, 02 June 2025
Posted 28 May 2025 AM
Updated results of an Australian-led trial highlighting long-term outcomes with Astellas' Xtandi in metastatic metastatic hormone-sensitive prostate cancer (mHSPC) will be presented at this year's American Society of Clinical Oncology (ASCO).
And in a double win for the drug, new data revealing longer-term follow-up results from an open-label extension of Astellas’ Phase 3 ARCHES study will also be presented.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.